HIV in South Africa: Part 2

Professor Francois Venter is back in Part 3 of our HIV series in which he continues to address South Africa's battles against HIV. Here he discusses his experience on how and when to initiate antiretroviral therapy, prophylaxis against opportunistic infection, routine monitoring and what the future of HIV management looks like in South Africa.

About our Guest:

Professor WD Francois Venter, MD, FCP, PhD is Executive Director of Wits Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training. His work involves health systems research and clinical trials, most recently involving the antiretrovirals dolutegravir, tenofovir alafenamide, cabotegravir, and doravirine. He leads multiple antiretroviral treatment optimisation studies and is currently working on new access programmes through private pharmacies within South Africa, patient linkage-to-care interventions, self-testing projects, as well as most recently on new large-scale primary care delivery platforms addressing hypertension, diabetes, obesity, hyperlipidaemia and HIV. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on men, women, children, young people, truckers, sex workers, and LGBTI communities. For over 20 years he has been an advisor to bodies such as the South African government, UNAIDS, and WHO, contributing to international, regional, and national HIV guidelines, and recently served as a member of the Ministerial Advisory Committee for COVID-19. He has an active interest in medical ethics and has been involved in several HIV-related human rights cases within the southern African region. He supervises Masters and PhD students and has over 200 publications, including first-author articles in major journals.

Resources:

SA HIV Clinicians society

ADVANCE STUDY

Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults:2023 update

Liverpool HIV Drug Interactions Checker

Visit the Microbe Mail website to sign up for updates

Follow on:

Instagram: Microbe_Mail

X/Twitter: @microbemail

Facebook: MicrobeMail

Tiktok: @microbe.mail

Watch this episode on YouTube: Microbe Mail